Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 85 | 2024 | 22389 | 4.600 |
Why?
|
Survivors | 40 | 2024 | 2383 | 3.550 |
Why?
|
Medical Oncology | 20 | 2024 | 2350 | 1.930 |
Why?
|
Primary Health Care | 17 | 2024 | 4748 | 1.440 |
Why?
|
Breast Neoplasms | 52 | 2022 | 21188 | 1.390 |
Why?
|
Physicians, Primary Care | 4 | 2023 | 625 | 1.230 |
Why?
|
Mammography | 12 | 2020 | 2434 | 1.190 |
Why?
|
Continuity of Patient Care | 7 | 2023 | 1076 | 1.180 |
Why?
|
Patient Education as Topic | 13 | 2020 | 2339 | 0.890 |
Why?
|
Delivery of Health Care | 19 | 2024 | 5375 | 0.890 |
Why?
|
Head and Neck Neoplasms | 4 | 2022 | 2931 | 0.880 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 9 | 2017 | 933 | 0.860 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2022 | 9442 | 0.850 |
Why?
|
Quality of Health Care | 7 | 2024 | 4339 | 0.850 |
Why?
|
Patient Care Planning | 7 | 2019 | 904 | 0.790 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2020 | 954 | 0.770 |
Why?
|
Patient Preference | 6 | 2022 | 947 | 0.730 |
Why?
|
Dental Care | 1 | 2024 | 286 | 0.730 |
Why?
|
Delayed Diagnosis | 4 | 2020 | 468 | 0.730 |
Why?
|
Patient Acceptance of Health Care | 9 | 2018 | 3235 | 0.700 |
Why?
|
Decision Making | 10 | 2020 | 3953 | 0.670 |
Why?
|
Patient-Centered Care | 5 | 2024 | 1447 | 0.670 |
Why?
|
Neoplasms, Second Primary | 6 | 2023 | 1060 | 0.660 |
Why?
|
Humans | 178 | 2024 | 768970 | 0.640 |
Why?
|
Long-Term Care | 4 | 2017 | 631 | 0.610 |
Why?
|
Quality of Life | 17 | 2024 | 13510 | 0.590 |
Why?
|
Health Services Accessibility | 5 | 2024 | 5522 | 0.590 |
Why?
|
Narration | 1 | 2019 | 223 | 0.560 |
Why?
|
Telemedicine | 5 | 2022 | 3110 | 0.560 |
Why?
|
Physical Endurance | 1 | 2019 | 370 | 0.550 |
Why?
|
Mastectomy, Segmental | 5 | 2017 | 960 | 0.530 |
Why?
|
Aftercare | 2 | 2019 | 921 | 0.530 |
Why?
|
Deductibles and Coinsurance | 4 | 2019 | 316 | 0.510 |
Why?
|
Attitude of Health Personnel | 9 | 2019 | 3928 | 0.510 |
Why?
|
Communication | 7 | 2018 | 3908 | 0.490 |
Why?
|
Workflow | 1 | 2020 | 859 | 0.490 |
Why?
|
Running | 1 | 2019 | 490 | 0.470 |
Why?
|
Attitude to Health | 3 | 2019 | 2025 | 0.470 |
Why?
|
Mass Screening | 8 | 2020 | 5457 | 0.460 |
Why?
|
Early Detection of Cancer | 10 | 2024 | 3238 | 0.460 |
Why?
|
United States | 37 | 2024 | 73186 | 0.420 |
Why?
|
General Practitioners | 1 | 2014 | 103 | 0.420 |
Why?
|
Practice Guidelines as Topic | 8 | 2024 | 7460 | 0.410 |
Why?
|
Breast Self-Examination | 2 | 2002 | 33 | 0.390 |
Why?
|
Patient Participation | 6 | 2020 | 1448 | 0.390 |
Why?
|
Referral and Consultation | 3 | 2020 | 3628 | 0.390 |
Why?
|
Insurance Coverage | 4 | 2018 | 1946 | 0.380 |
Why?
|
Patient Care Management | 2 | 2017 | 304 | 0.380 |
Why?
|
Medical Indigency | 1 | 2011 | 63 | 0.380 |
Why?
|
Internal Medicine | 3 | 2021 | 1064 | 0.360 |
Why?
|
Appointments and Schedules | 1 | 2014 | 443 | 0.360 |
Why?
|
Mastectomy | 7 | 2008 | 1850 | 0.350 |
Why?
|
Evidence-Based Medicine | 4 | 2019 | 3709 | 0.350 |
Why?
|
Population Surveillance | 2 | 2020 | 2597 | 0.350 |
Why?
|
Evidence-Based Practice | 1 | 2014 | 500 | 0.340 |
Why?
|
Physicians | 4 | 2019 | 4607 | 0.340 |
Why?
|
Ovarian Neoplasms | 2 | 2022 | 4919 | 0.340 |
Why?
|
Employment | 1 | 2016 | 1114 | 0.330 |
Why?
|
Pandemics | 6 | 2022 | 8749 | 0.330 |
Why?
|
Insurance, Health | 5 | 2019 | 2518 | 0.330 |
Why?
|
Palliative Care | 4 | 2024 | 3644 | 0.330 |
Why?
|
Medication Adherence | 2 | 2011 | 2192 | 0.330 |
Why?
|
Female | 94 | 2024 | 397515 | 0.330 |
Why?
|
Terminal Care | 1 | 2021 | 1772 | 0.320 |
Why?
|
Clinical Competence | 3 | 2023 | 4860 | 0.320 |
Why?
|
Physician-Patient Relations | 7 | 2016 | 3269 | 0.320 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2014 | 1093 | 0.310 |
Why?
|
Survival Rate | 8 | 2017 | 12873 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3118 | 0.310 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2543 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3241 | 0.300 |
Why?
|
Vulvar Neoplasms | 2 | 2024 | 266 | 0.300 |
Why?
|
Patient Compliance | 4 | 2014 | 2701 | 0.290 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2014 | 4056 | 0.290 |
Why?
|
Uterine Neoplasms | 3 | 2023 | 1424 | 0.290 |
Why?
|
Patient Care Team | 3 | 2017 | 2528 | 0.290 |
Why?
|
Tamoxifen | 2 | 2011 | 967 | 0.290 |
Why?
|
Aromatase Inhibitors | 1 | 2011 | 519 | 0.280 |
Why?
|
Patient Satisfaction | 6 | 2021 | 3492 | 0.280 |
Why?
|
Women's Health | 4 | 2009 | 2081 | 0.280 |
Why?
|
Physicians, Family | 1 | 2009 | 349 | 0.280 |
Why?
|
Carcinoma in Situ | 2 | 2009 | 788 | 0.270 |
Why?
|
Breast | 4 | 2019 | 1976 | 0.270 |
Why?
|
Middle Aged | 62 | 2024 | 223737 | 0.270 |
Why?
|
Fear | 3 | 2020 | 1493 | 0.270 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 957 | 0.270 |
Why?
|
Adaptation, Psychological | 6 | 2022 | 2666 | 0.260 |
Why?
|
Aged | 50 | 2024 | 171786 | 0.260 |
Why?
|
Adult | 52 | 2024 | 223851 | 0.260 |
Why?
|
Research | 5 | 2023 | 1981 | 0.250 |
Why?
|
Interdisciplinary Communication | 2 | 2014 | 937 | 0.240 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2018 | 1535 | 0.240 |
Why?
|
Lymphoma | 1 | 2014 | 1900 | 0.240 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.240 |
Why?
|
Nomograms | 3 | 2015 | 236 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2023 | 2044 | 0.230 |
Why?
|
Internet | 3 | 2014 | 3112 | 0.230 |
Why?
|
Patient Care | 1 | 2009 | 629 | 0.220 |
Why?
|
Endometrial Neoplasms | 3 | 2023 | 1386 | 0.220 |
Why?
|
Women | 1 | 2005 | 225 | 0.220 |
Why?
|
Estrogen Replacement Therapy | 2 | 2009 | 1209 | 0.220 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1196 | 0.210 |
Why?
|
Prostatic Neoplasms | 4 | 2020 | 11230 | 0.210 |
Why?
|
Health Services Research | 4 | 2021 | 1818 | 0.210 |
Why?
|
Drug Costs | 1 | 2011 | 1198 | 0.210 |
Why?
|
Health Expenditures | 4 | 2018 | 2396 | 0.200 |
Why?
|
Physical Examination | 1 | 2008 | 1262 | 0.200 |
Why?
|
Carcinosarcoma | 1 | 2023 | 108 | 0.200 |
Why?
|
Carcinoma, Endometrioid | 2 | 2023 | 277 | 0.200 |
Why?
|
Documentation | 1 | 2008 | 917 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 36854 | 0.190 |
Why?
|
Policy | 2 | 2023 | 514 | 0.190 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 26395 | 0.190 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2023 | 218 | 0.190 |
Why?
|
Health Maintenance Organizations | 3 | 2009 | 657 | 0.170 |
Why?
|
Latin America | 1 | 2021 | 416 | 0.170 |
Why?
|
Erythema Nodosum | 1 | 2000 | 32 | 0.170 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2000 | 72 | 0.170 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13698 | 0.170 |
Why?
|
Neoplasm Staging | 11 | 2019 | 11262 | 0.160 |
Why?
|
Aged, 80 and over | 22 | 2020 | 59739 | 0.160 |
Why?
|
Managed Care Programs | 3 | 2014 | 941 | 0.160 |
Why?
|
Young Adult | 11 | 2022 | 60131 | 0.160 |
Why?
|
Oral Health | 1 | 2024 | 493 | 0.150 |
Why?
|
Education, Continuing | 1 | 2019 | 115 | 0.150 |
Why?
|
Needs Assessment | 3 | 2018 | 1143 | 0.150 |
Why?
|
Reproduction | 1 | 2023 | 646 | 0.150 |
Why?
|
Psychotherapy, Group | 1 | 2002 | 417 | 0.150 |
Why?
|
Sensitivity and Specificity | 7 | 2024 | 14752 | 0.150 |
Why?
|
Mental Processes | 1 | 2019 | 246 | 0.150 |
Why?
|
Life Style | 2 | 2020 | 3931 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 716 | 0.150 |
Why?
|
Hypothyroidism | 1 | 2022 | 667 | 0.140 |
Why?
|
Male | 32 | 2024 | 365203 | 0.140 |
Why?
|
Depression | 5 | 2023 | 8231 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 476 | 0.130 |
Why?
|
Health Services Needs and Demand | 3 | 2019 | 1407 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 260 | 0.130 |
Why?
|
Oral Hygiene | 1 | 2017 | 132 | 0.130 |
Why?
|
Attitude | 2 | 2014 | 772 | 0.130 |
Why?
|
Hot Flashes | 2 | 2009 | 330 | 0.130 |
Why?
|
Models, Theoretical | 2 | 2010 | 3580 | 0.130 |
Why?
|
Longitudinal Studies | 5 | 2019 | 14794 | 0.130 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 1640 | 0.130 |
Why?
|
Europe | 1 | 2022 | 3441 | 0.130 |
Why?
|
Curriculum | 2 | 2021 | 3782 | 0.120 |
Why?
|
Health Surveys | 5 | 2019 | 4055 | 0.120 |
Why?
|
Health Care Surveys | 4 | 2016 | 2437 | 0.120 |
Why?
|
Delphi Technique | 3 | 2024 | 890 | 0.120 |
Why?
|
Forecasting | 2 | 2017 | 2945 | 0.120 |
Why?
|
Information Dissemination | 1 | 2023 | 1141 | 0.120 |
Why?
|
China | 1 | 2020 | 2395 | 0.110 |
Why?
|
Professional Role | 1 | 2017 | 316 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3554 | 0.110 |
Why?
|
Consumer Health Information | 1 | 2016 | 215 | 0.110 |
Why?
|
SEER Program | 3 | 2014 | 1473 | 0.110 |
Why?
|
Quality Assurance, Health Care | 2 | 2014 | 2182 | 0.110 |
Why?
|
Consensus | 3 | 2022 | 3214 | 0.110 |
Why?
|
Anxiety | 4 | 2023 | 4672 | 0.110 |
Why?
|
Educational Status | 1 | 2021 | 2515 | 0.110 |
Why?
|
Vulnerable Populations | 1 | 2019 | 718 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1476 | 0.100 |
Why?
|
Medicare | 1 | 2011 | 6888 | 0.100 |
Why?
|
Healthcare Disparities | 2 | 2020 | 3421 | 0.100 |
Why?
|
Osteoporosis | 1 | 2022 | 1606 | 0.100 |
Why?
|
Health Personnel | 4 | 2019 | 3383 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 2020 | 1437 | 0.100 |
Why?
|
Boston | 3 | 2011 | 9377 | 0.100 |
Why?
|
Cohort Studies | 10 | 2019 | 41808 | 0.100 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39394 | 0.100 |
Why?
|
Adolescent | 12 | 2024 | 89244 | 0.100 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1907 | 0.100 |
Why?
|
Caregivers | 3 | 2022 | 2308 | 0.090 |
Why?
|
Data Collection | 2 | 2012 | 3324 | 0.090 |
Why?
|
Developing Countries | 1 | 2024 | 2911 | 0.090 |
Why?
|
American Cancer Society | 2 | 2022 | 69 | 0.090 |
Why?
|
Exercise | 4 | 2022 | 5954 | 0.090 |
Why?
|
Self Report | 2 | 2020 | 3773 | 0.090 |
Why?
|
Anthracyclines | 1 | 2012 | 286 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1806 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2020 | 2008 | 0.090 |
Why?
|
Postmenopause | 2 | 2009 | 2519 | 0.080 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 97 | 0.080 |
Why?
|
Risk Assessment | 8 | 2024 | 24333 | 0.080 |
Why?
|
Insurance Claim Review | 1 | 2014 | 746 | 0.080 |
Why?
|
Pilot Projects | 4 | 2024 | 8748 | 0.080 |
Why?
|
Socioeconomic Factors | 5 | 2018 | 7861 | 0.080 |
Why?
|
Comorbidity | 3 | 2020 | 10592 | 0.080 |
Why?
|
Group Practice, Prepaid | 1 | 2008 | 15 | 0.080 |
Why?
|
Neoplasm Invasiveness | 5 | 2017 | 3629 | 0.080 |
Why?
|
Health Behavior | 2 | 2018 | 2649 | 0.080 |
Why?
|
Pregnancy Complications | 3 | 2000 | 2974 | 0.080 |
Why?
|
Current Procedural Terminology | 1 | 2009 | 101 | 0.080 |
Why?
|
Drug Substitution | 1 | 2011 | 291 | 0.080 |
Why?
|
Washington | 1 | 2009 | 315 | 0.080 |
Why?
|
Interprofessional Relations | 2 | 2014 | 997 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2024 | 5864 | 0.070 |
Why?
|
Melanoma | 2 | 2024 | 5709 | 0.070 |
Why?
|
Risk Factors | 13 | 2018 | 74976 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3253 | 0.070 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2017 | 1189 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6214 | 0.070 |
Why?
|
Genetic Counseling | 1 | 2011 | 634 | 0.070 |
Why?
|
Prognosis | 8 | 2016 | 30046 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4926 | 0.070 |
Why?
|
Disease Progression | 2 | 2022 | 13674 | 0.070 |
Why?
|
Genital Neoplasms, Female | 2 | 2024 | 538 | 0.070 |
Why?
|
Time Factors | 4 | 2018 | 40261 | 0.060 |
Why?
|
Community Health Services | 1 | 2011 | 659 | 0.060 |
Why?
|
Intention | 1 | 2008 | 348 | 0.060 |
Why?
|
Psychometrics | 1 | 2015 | 3066 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 1793 | 0.060 |
Why?
|
Gynecology | 2 | 2010 | 534 | 0.060 |
Why?
|
Inservice Training | 1 | 2008 | 375 | 0.060 |
Why?
|
Professional Practice | 1 | 2007 | 314 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2017 | 2085 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2023 | 65480 | 0.060 |
Why?
|
Phenotype | 1 | 2023 | 16731 | 0.060 |
Why?
|
Colorectal Neoplasms | 2 | 2014 | 6982 | 0.060 |
Why?
|
Registries | 4 | 2019 | 8384 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3270 | 0.060 |
Why?
|
Hormone Replacement Therapy | 1 | 2010 | 757 | 0.060 |
Why?
|
Child | 7 | 2024 | 80960 | 0.060 |
Why?
|
Obstetrics | 2 | 2010 | 682 | 0.060 |
Why?
|
Biopsy | 4 | 2019 | 6805 | 0.060 |
Why?
|
Medical History Taking | 1 | 2008 | 779 | 0.060 |
Why?
|
Ethics Committees, Research | 1 | 2005 | 196 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2009 | 2932 | 0.060 |
Why?
|
Paget Disease, Extramammary | 1 | 2024 | 51 | 0.060 |
Why?
|
International Classification of Diseases | 1 | 2009 | 936 | 0.050 |
Why?
|
Biomedical Research | 1 | 2019 | 3463 | 0.050 |
Why?
|
Incidence | 4 | 2018 | 21547 | 0.050 |
Why?
|
Life Expectancy | 1 | 2010 | 1249 | 0.050 |
Why?
|
Physician's Role | 1 | 2009 | 926 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2008 | 725 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11886 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20245 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9213 | 0.050 |
Why?
|
Computers, Handheld | 1 | 2024 | 211 | 0.050 |
Why?
|
International Educational Exchange | 1 | 2002 | 54 | 0.050 |
Why?
|
Qualitative Research | 2 | 2013 | 3143 | 0.050 |
Why?
|
California | 2 | 2020 | 1443 | 0.050 |
Why?
|
Health Status | 3 | 2010 | 4095 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 2606 | 0.050 |
Why?
|
Retrospective Studies | 13 | 2020 | 81903 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2014 | 2057 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2017 | 3838 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4064 | 0.050 |
Why?
|
Developed Countries | 1 | 2024 | 452 | 0.050 |
Why?
|
Program Evaluation | 2 | 2019 | 2508 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5434 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2006 | 971 | 0.050 |
Why?
|
Menopause | 1 | 2009 | 1656 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2007 | 985 | 0.040 |
Why?
|
beta 2-Glycoprotein I | 1 | 2000 | 28 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9756 | 0.040 |
Why?
|
Mass Media | 1 | 2003 | 303 | 0.040 |
Why?
|
Patient Selection | 1 | 2012 | 4265 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2022 | 395 | 0.040 |
Why?
|
Internship and Residency | 1 | 2000 | 5956 | 0.040 |
Why?
|
Massachusetts | 2 | 2010 | 8894 | 0.040 |
Why?
|
Connecticut | 1 | 2000 | 365 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2241 | 0.040 |
Why?
|
Medical Records | 1 | 2005 | 1411 | 0.040 |
Why?
|
New England | 1 | 2002 | 1058 | 0.040 |
Why?
|
Disease Management | 1 | 2010 | 2537 | 0.040 |
Why?
|
Heart Failure | 2 | 2014 | 11879 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 834 | 0.040 |
Why?
|
Problem-Based Learning | 1 | 2002 | 360 | 0.040 |
Why?
|
Case-Control Studies | 6 | 2015 | 22296 | 0.040 |
Why?
|
Age Factors | 4 | 2020 | 18435 | 0.040 |
Why?
|
Family Practice | 2 | 2010 | 509 | 0.030 |
Why?
|
Logistic Models | 3 | 2018 | 13318 | 0.030 |
Why?
|
Osteitis | 1 | 1996 | 33 | 0.030 |
Why?
|
Mammaplasty | 1 | 2007 | 1263 | 0.030 |
Why?
|
Hyperostosis | 1 | 1996 | 29 | 0.030 |
Why?
|
Survival Analysis | 2 | 2016 | 10115 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10400 | 0.030 |
Why?
|
Quadruplets | 1 | 1996 | 9 | 0.030 |
Why?
|
Algorithms | 2 | 2014 | 14201 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2000 | 992 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1216 | 0.030 |
Why?
|
Odds Ratio | 3 | 2014 | 9684 | 0.030 |
Why?
|
Genetic Testing | 2 | 2012 | 3591 | 0.030 |
Why?
|
ROC Curve | 2 | 2014 | 3629 | 0.030 |
Why?
|
Recurrence | 2 | 2016 | 8513 | 0.030 |
Why?
|
Synovitis | 1 | 1996 | 217 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2021 | 1119 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 300 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13594 | 0.030 |
Why?
|
Pregnancy | 5 | 2019 | 30265 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2019 | 577 | 0.030 |
Why?
|
Self Efficacy | 1 | 2019 | 643 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1557 | 0.030 |
Why?
|
Societies, Medical | 2 | 2019 | 3968 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2012 | 1737 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8559 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1399 | 0.030 |
Why?
|
MEDLINE | 1 | 2013 | 119 | 0.030 |
Why?
|
Hysterectomy | 1 | 2019 | 866 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 549 | 0.030 |
Why?
|
Emotions | 1 | 2005 | 2768 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1995 | 410 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1140 | 0.030 |
Why?
|
Clinical Coding | 1 | 2014 | 188 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1669 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2014 | 210 | 0.020 |
Why?
|
Glycoproteins | 1 | 2000 | 2202 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 428 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2023 | 2749 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2019 | 5323 | 0.020 |
Why?
|
Health Plan Implementation | 1 | 2014 | 338 | 0.020 |
Why?
|
Acne Vulgaris | 1 | 1996 | 352 | 0.020 |
Why?
|
Incidental Findings | 1 | 2016 | 697 | 0.020 |
Why?
|
Brachytherapy | 1 | 2019 | 1224 | 0.020 |
Why?
|
Autoantibodies | 1 | 2000 | 2120 | 0.020 |
Why?
|
Aspirin | 1 | 2022 | 3135 | 0.020 |
Why?
|
Genes, BRCA2 | 1 | 2014 | 593 | 0.020 |
Why?
|
Education, Medical | 1 | 2002 | 1742 | 0.020 |
Why?
|
Income | 1 | 2019 | 1879 | 0.020 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 756 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15879 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 18068 | 0.020 |
Why?
|
Diet | 2 | 2022 | 8088 | 0.020 |
Why?
|
Professional-Family Relations | 1 | 2013 | 501 | 0.020 |
Why?
|
Dyspareunia | 1 | 2009 | 48 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 202 | 0.020 |
Why?
|
Medical Audit | 1 | 2010 | 454 | 0.020 |
Why?
|
Psoriasis | 1 | 1996 | 926 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 682 | 0.020 |
Why?
|
Health Resources | 1 | 2014 | 951 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1798 | 0.020 |
Why?
|
Sweating | 1 | 2009 | 155 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2000 | 4568 | 0.020 |
Why?
|
Patient Transfer | 1 | 2014 | 792 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2921 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1913 | 0.020 |
Why?
|
Poverty | 1 | 2019 | 2720 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5100 | 0.020 |
Why?
|
Awareness | 1 | 2011 | 653 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2875 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 2525 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6401 | 0.020 |
Why?
|
Complementary Therapies | 1 | 2010 | 487 | 0.020 |
Why?
|
Skin | 1 | 2000 | 4506 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9621 | 0.020 |
Why?
|
Postal Service | 1 | 2005 | 96 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2360 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2914 | 0.010 |
Why?
|
Probability | 1 | 2010 | 2483 | 0.010 |
Why?
|
Peer Group | 1 | 2010 | 698 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2016 | 1886 | 0.010 |
Why?
|
Sexuality | 1 | 2006 | 179 | 0.010 |
Why?
|
Mental Health | 1 | 2018 | 3275 | 0.010 |
Why?
|
Breast Diseases | 1 | 2006 | 442 | 0.010 |
Why?
|
Psychology | 1 | 2005 | 354 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3860 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8055 | 0.010 |
Why?
|
Treatment Failure | 1 | 2009 | 2664 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2005 | 15889 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2394 | 0.010 |
Why?
|
Family | 1 | 2013 | 3208 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2005 | 368 | 0.010 |
Why?
|
Russia | 1 | 2002 | 386 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15471 | 0.010 |
Why?
|
Breast Implants | 1 | 2005 | 414 | 0.010 |
Why?
|
Body Image | 1 | 2006 | 646 | 0.010 |
Why?
|
Stroke Volume | 1 | 2014 | 5622 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2007 | 2744 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1445 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3721 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2009 | 1812 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12095 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2012 | 11116 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12562 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6291 | 0.010 |
Why?
|
Indomethacin | 1 | 1996 | 323 | 0.010 |
Why?
|
Aging | 1 | 1995 | 8745 | 0.010 |
Why?
|
Databases, Factual | 1 | 2012 | 8094 | 0.010 |
Why?
|
Program Development | 1 | 2002 | 1300 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2012 | 4879 | 0.010 |
Why?
|
Chronic Disease | 1 | 2009 | 9384 | 0.010 |
Why?
|
France | 1 | 1996 | 497 | 0.010 |
Why?
|
Syndrome | 1 | 1996 | 3274 | 0.010 |
Why?
|
Birth Weight | 1 | 1996 | 2121 | 0.000 |
Why?
|
Pregnancy Outcome | 1 | 1996 | 2974 | 0.000 |
Why?
|